In NSCLC harboring an EGFR mutation sensitive to tyrosine kinase inhibitors (TKIs), namely exon 19 deletions or L858R point mutation, first line treatment with osimertinib, a third-generation TKI, improved OS by nearly seven months [11]. Here, EGFR is linked to non-small cell lung carcinoma.